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Abstract 
 
Sprint intensity interval training (SIT) is reported to improve blood glucose control and may 
be a useful public health tool. The sirtuins and associated genes are emerging as key players 
in blood glucose control. This study investigated the interplay between the sirtuin/NAD 
system and individual variation in insulin sensitivity responses after SIT in young healthy 
individuals. Before and after 4 weeks of SIT body mass and fat percentage were measured 
and oral glucose tolerance tests (OGTT) performed in 20 young healthy participants (7 
females). Blood gene expression profiles (all 7 mammalian sirtuin genes and 15 enzymes 
involved in conversion of tryptophan, bioavailable vitamin B3 and metabolic precursors to 
NAD). NAD/NADP was measured in whole blood. Significant reductions in body weight and 
body fat post-SIT were associated with altered lipid profiles, NAD/NADP and regulation of 
components of the sirtuin/NAD system (NAMPT, NMNAT1, CD38 and ABCA1). Variable 
improvements in measured metabolic health parameters were evident and attributed to 
different responses in males and females, together with marked inter-individual variation in 
responses of the sirtuin/NAD system to SIT.  
 
Keywords: insulin sensitivity, interval exercise, body composition, sirtuin system, inter-
individual variation, GeXP 
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Introduction 
 
Insulin resistance (IR) is a major risk factor for the development of type 2 diabetes (T2D) and 
people with IR and/or T2D have been found to have 2-4 fold greater risk of CVD with 80% 
of people with T2D dying from CVD (Capewell  et al. 2009). T2D prevalence is rising, with 
~400 million global cases (projected to rise to ~600 million cases by 2035), it accounts for 
>10% of healthcare spending (International Diabetes Federation, 2013). Lack of physical 
activity and excess weight are the main factors thought to be responsible for this high, and 
increasing, prevalence. For this reason, and to achieve many of the other health benefits, 
people are recommended to participate in 150 minutes of moderate or 75 minutes of vigorous 
intensity exercise per week. 
 
Indeed, moderate intensity exercise (150 min/week) has been shown to be effective in 
reducing T2D to a greater extent than treatment with metformin (Knowler et al. 2002). Sprint 
interval training (SIT) has emerged as a strategy that can improve exercise performance, 
glucose control, insulin sensitivity, mitochondrial capacity, endothelial function and reduce 
postprandial triacylglycerol in healthy individuals after as little as 2 weeks (Babraj et al. 
2009; Burgomaster et al. 2005; Gabriel et al. 2012; Little et al. 2010; Tjønna et al. 2008). A 
wealth of evidence demonstrates the health benefits of SIT, but inter-individual variation in 
responses implies interactions with genetics (Timmons et al. 2010) and requires investigation 
to optimise SIT interventions. 
 
SIRTUIN1 and the enzymes crucial in generating the sirtuin cofactor, nicotinamide adenine 
dinucleotide (NAD), have recently been implicated in diet and age-induced pathogenesis of 
T2D (Dong 2012; Haigis and Sinclair 2010; Huynh  et al. 2013). The sirtuin/NAD system is 
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also responsive to altered glucose regulation during the development of diet induced obesity 
(Drew et al 2016). Increased physical activity is associated with beneficial effects on 
metabolic health that are associated with altered regulation of the sirtuin system (Koltai et al. 
2010). Further research is necessary to decipher the components of the sirtuin system that 
respond to exercise interventions that improve metabolic health. The sirtuin/NAD system is 
compromised by interactions with individual genetics (Kilic et al. 2014) since all seven 
sirtuins (SIRT1-7) and NAD biosynthesis enzymes are subject to genetic variation. Sirtuins 
are dependent on an adequate supply of NAD cofactors for enzymatic activity to regulate 
cellular processes linking them to the energy status of cells via cellular generation of 
nicotinamide. NAD generation is dependent on dietary intake of tryptophan and bioavailable 
niacin, but importantly NAD can be regenerated, independent of diet, by activation of salvage 
pathways that are upregulated in response to exercise (Hubbard and Sinclair 2014).  
 
Recent technological advances present opportunities to predict health status and benefits 
conferred by lifestyle interventions using gene expression profiling of whole blood (Drew et 
al 2012). Considering the difficulties in accessing target tissues in human subjects this 
presents a strategy warranting consideration for research to identify individual responses to 
diet and lifestyle interventions. Consequently, our lab has been conducting studies to 
determine the feasibility of whole blood gene expression profiling to identify responses to 
interventions in humans (Drew et al 2014). This led to identification of variable levels of 
SIRT1 in human whole blood from apparently healthy individuals (Drew et al. 2014, Andraos 
et al 2016). Further investigation revealed that individuals with low SIRT1 exhibited higher 
levels of plasma inflammatory markers (TNFα), deregulated metabolic responses to food 
consumption (absence of a postprandial SOCS3 response), elevated p53 and low levels of 
high density lipoprotein cholesterol (HDL), factors indicative of reduced health status and 
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metabolic stress (Drew et al. 2014, Andraos et al 2016). Importantly, these studies have 
demonstrated stable whole blood gene expression profiles that characterise individual 
subjects and their individual responses to dietary intervention.  
 
Thus the aim of this study was to determine changes in anthropometric and metabolic 
measures in response to SIT. Secondly, the study aimed to determine whether these changes 
were associated with modulation of the sirtuin/NAD system using human whole blood gene 
expression profiling. We hypothesised that improvements in outcome measures following 
SIT would be associated with specific changes in components of the sirutin/NAD system.  
 
Materials and Methods 
 
Study population  
 
Twenty recreationally active, but not specifically trained (not engaged in physical training to 
increase strength, aerobic fitness, speed, fitness or skillful practice for a specific sport or 
activity), participants aged 18-35 years, non-smokers, free of cardiovascular, metabolic or 
haematological disorders were recruited. The study was approved by the University of 
Aberdeen College Ethical Review Board. All participants were fully informed of the aims, 
risks and discomfort associated with the investigation before providing written informed 
consent. 
 
Pre-Experimental and Post Training Procedures 
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Participants were asked to complete a 4 day estimated food diary (2 weekdays and 2 weekend 
days, on 4 consecutive days) directly preceding the SIT intervention. Recorded food diary 
data was input into NetWISP dietary software analysis and patterns of daily food and nutrient 
intake were then determined, with specific reference to macronutrients and micronutrients 
associated with NAD generation (e.g. niacin). Participants were asked to maintain their 
habitual dietary intake and physical activity patterns for the duration of the study.  
 
Participants attended the laboratory in the morning after an overnight fast (from 10pm the 
previous evening) having abstained from strenuous exercise, caffeine and alcohol for 24h. 
Blood samples and the measurements detailed below were obtained no more than 1 week 
prior to the SIT intervention and 2 days after the final training session. Body mass and height 
were measured using standard scales and stadiometers. Subcutaneous body fat was measured 
at four points on the body (biceps, triceps, suprailiac and subscapular) to the nearest 0.2mm 
using skinfold callipers (Harpenden) and converted to body fat percentage using the 
equations of (Durnin and Womersley  1974). Waist/hip ratio was assessed using a tape to 
measure hip and waist circumferences to the nearest 1cm. An oral glucose tolerance test 
(OGTT) was performed. Baseline venous blood samples were collected (K3 EDTA and Na 
Heparin Vacuettes, Greiner Bio-One and Paxgene RNA tube, PreAnalytiX) before ingestion 
of a 75g glucose bolus (436ml Lucozade Original). Venous blood samples were then 
collected at 60, 90 and 120 min after the consumption of the 75g glucose bolus. Whole blood 
collected in Na Heparin tubes were snap frozen prior to NAD assay (see below). Plasma was 
prepared by centrifugation (Eppendorf Centrifuge 5702/R) at 4000rpm, 4°C for 10 minutes, 
aliquoted and stored -20°C. Glucose and insulin concentrations were then measured using 
commercially available assays (see below). Blood collected in the Paxgene tubes was stored 
according to the manufacturer’s instructions prior to total RNA extraction (see below).  
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Exercise Training 
 
The SIT program was performed using a cycle ergometer and involved 3 sessions per week 
for 4 weeks. The participants warmed up for 3 mins at a workload of 50 Watts, followed by 
4-6 (building from 4 to 6 over the first 6 sessions) maximal 30s sprints at a resistance 
equivalent to 7.5% of body mass with 3 minutes unloaded cycling between sets. This was 
followed by a 3 min cool down at 50 Watts. Participants were instructed to perform each 
sprint maximally with encouragement given during each sprint. The intensity of each bout 
was not recorded. Once carrying out 6 sprints each session lasted 24 mins. Participants 
performed this protocol three times each week for a 4-week period and all sessions were 
supervised.  
 
Glucose and Insulin Analysis  
 
Glucose (Human Glucose, Randox, UK) and insulin (Human Insulin, Mercodia UK) were 
assayed in plasma using commercially available kits according to the manufacturer’s 
instructions and spectrophotometers, a Camspec M330B and a Biotek, Synergy HT multi-
mode microplate reader respectively.  
 
The AUC for both glucose and insulin concentrations during the OGTT were calculated using 
the trapezoid rule. Insulin sensitivity was estimated using the Cederholm index (Equation 1): 
 
Equation 1: ISICederholm = 75000 + (G0 – G120) x 180 x 0.19 x BW/120 X GMean x log (IMean) 
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Where BW = body weight, G0 and G120 = plasma glucose concentration at 0 and 120 minutes 
(mmol.l
-1
) respectively, and IMean and GMean = mean insulin (mU.l
-1
) and glucose (mmol.l
-1
) 
concentrations during the OGTT respectively. 
 
Lipid profiling  
 
Lipid profiles (total cholesterol, HDL, LDL, triglycerides, Non-HDL and LDL: HDL ratio) of 
baseline (pre and post SIT) were measured from whole blood samples using commercially 
available kits (Alere Cholestech LDX® Lipid Profile Cassettes), in accordance with 
manufacturer’s instructions. 
 
Blood expression profiling of sirtuin and NAD biosynthetic enzyme genes  
 
Total RNA was extracted from human whole blood samples collected at baseline (pre and 
post SIT) and 60 min post OGTT in PAXgene® blood RNA tubes (PreAnalytiX GmbH) 
(2.5ml) using a PAXgene Blood RNA Kit (Qiagen, Crawley, UK), incorporating DNase 
digestion. RNA quality was assessed using a NanoDrop Spectrophotometer (NanoDrop 
Technologies, LabTech International, UK) and the Agilent Bioanalyser (Agilent 
Technologies, Bracknell, UK). Whole blood total RNA (50 ng) was assayed for sirtuin and 
NAD biosynthetic enzyme gene targets using the GenomeLab™ GeXP Genetic Analysis 
System (Beckman Coulter) and our in-house custom designed assay, the hSIRTNADPlex. 
The hSIRTNADPlex incorporates 25 gene targets, including all 7 mammalian sirtuin genes 
(SIRT1-7), 15 enzymes involved in conversion of tryptophan, niacin, the novel vitamin, 
nicotinamide riboside, and metabolic precursors to NAD, together with 3 reference genes and 
a synthetic reference messenger RNA transcript for measuring relative quantitation of gene 
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expression and reaction efficiencies respectively (Supplementary File S1). Details of the the 
GenomeLab System for design of in-house custom designed multiplex assays and application 
to conduct blood gene expression profiling have been published previously (Drew et al. 2011; 
Drew et al. 2014) and are described in Supplementary File S2. Fragment analysis of the 
generated hSIRTNADPlex PCR products was conducted using the Beckman Coulter CEQ 
8000 GeXP Genetic Analysis system. The raw data generated using the GenomeLab™ GeXP 
Series Software Suite v11.0 was then exported using the GeXP Fragment Analysis Module 
and normalized using the GeXP Data Tool. 
 
NAD and NADP assay  
 
NAD and NADP were assessed in whole blood (50ul) at baseline (pre and post SIT) using 
methods described by Jacobsen and Jacobsen (1997) with modifications as described by 
Creeke et al. 2007). Spectrophotometric readings were assayed using an MRX plate reader 
(Dynatech Laboratories). 
 
Bradford Assay 
 
Commercially available reagents (Bradford Reagent, PBS, BSA; Sigma-Aldrich® UK) and 
96-well microtiter plates (F96 Maxisorp NUNC immunoplate, VWR) were used to determine 
total protein content of plasma samples pre and post SIT intervention using standard Bradford 
assay procedure. Absorbance was measured using a standard curve and plate reader (MRX 
plate reader, Dynatech Laboratories) at 595nm. 
 
NAMPT and Vitamin B3  
Page 10 of 39
11 
 
 
Vitamin B3 and NAMPT concentrations were determined via commercially available 
enzyme-linked immunosorbent assay (ELISA) kits (RayBio® and MyBioSource®, USA) 
according to the manufacturer’s instructions. NAMPT concentrations were subsequently 
standardised against total protein content assessed by Bradford assay.  
 
Statistics 
 
Plasma glucose and insulin responses to the pre-training and post-training OGTTs were 
analysed using two-way repeated measures ANOVA with post hoc t-tests. Paired t-tests were 
used to assess significant changes in anthropometric measures, metabolic biomarkers, gene 
expression and other relevant markers from pre to post SIT intervention (p<0.05). Principal 
Component Analysis (PCA) and Partial Least Squares (PLS) analyses were performed using 
SIMCA-P+ 12.0 software (MKS Instruments UK Ltd, Cheshire). PCA was conducted with 
normalised gene expression and PLS was performed using normalised gene expression data 
(Y) and anthropometric and metabolic marker data (X). Pearson correlations were calculated 
using SPSS. 
 
Results 
 
Study participants 
 
Twenty individuals were recruited to participate in the study (13 males and 7 females) and all 
completed (100% attendance at sessions) the 4 week supervised SIT intervention. The mean 
±SD age was 22.8 ±2.8 years, height was 1.77±0.11 m and weight was 73.6±14.3 kg. 
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Food diaries 
 
Estimated daily macronutrient and niacin intakes were calculated from 14 of the 20 
participants (7 female) that returned completed food diaries (Table 1). The data collected 
indicated mean macronutrient intakes within the normal range recommended intakes prior to 
study participation. The % of total daily energy ± SEM intakes were fat 33.6 ± 2.3, protein 
17.8 ± 0.9 and carbohydrate 44.5 ± 2.5. Individual niacin intake was varied, with mean niacin 
intake 27.8 ± 3.1 mg/day, ranging from 14.84 – 60.34 mg/day. Participants were asked to 
maintain their habitual dietary intake patterns for the duration of the SIT intervention.  
 
Anthropometric data 
 
Anthropometric measurements (n=20) pre and post SIT are shown (Table 2). Significant 
reductions in body mass (p=0.023) and body fat percentage (p=0.0004) were seen after SIT 
(Table 2). No significant differences were observed in BMI (p=0.07) or waist:hip ratio 
(p=0.19) post SIT (Table 2). However, review of individual responses to SIT indicated that 
there was inter-individual variation, with some, but not all participants responding favourably 
(Figures 1A-D).  
 
Glucose, insulin and insulin sensitivity 
 
Mean glucose, insulin (Table 3) and glucose concentrations following OGTT (Figure 2A) 
were not significantly altered in response to SIT. Glucose area under the curve (AUC) did not 
significantly change post SIT (p=0.34). Mean glucose AUC change post SIT was -15.8 ± 
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72.9mmol.L
-1
. However, inter-individual changes were observed (range, -162.9mmol.L
-1
 to 
+153.2mmol.L
-1
) in glucose AUC with 13 participants showing a reduction (Figure 2B). 
Mean insulin AUC was also not significantly reduced (p=0.38) post SIT (Figure 2C).  
However, despite the lack of significant decreases, mean insulin AUC change was -194.5 ± 
971.3mU.L
-1
, with 14 participants having reduced insulin AUC post SIT (range: -1679mU.L
-1
 
to +2302mU.L
-1
) (Figure 2D). The mean insulin sensitivity increase following 4 weeks SIT 
was 2.62 ± 13.6mg.mUl
-1
.min, but this was not significant (p=0.40) (Figure 2E). It was noted 
that 12 of the 20 participants had increased insulin sensitivity post SIT (range: +25.7mg.mUl
-
1
.min to -23mg.mUl
-1
.min) (Figure 2F). 
 
Lipid profiling 
 
Lipid profiles, total cholesterol (p=0.42), HDL (p=0.95), LDL (p=0.23), triglycerides 
(p=0.30), non HDL (0.44) and LDL: HDL ratios (p=0.63) were not significantly altered in 
response to SIT (n=19) (Table 3) and a wide range of responses observed (data not shown). 
 
Transcriptional responses of SIRT/NAD system to SIT  
 
The hSIRTNADPlex gene expression profiles measured in whole blood total RNA (RIN 
values 7.0-9.3) pre and post SIT and post OGTT normalised to UBE2D2, established as a 
stably expressed transcript in blood using geNORM (Pattyn et al. 2003), are shown (Figure 
3). Small, but significant changes in response to SIT and OGTT were observed (Figure 3). 
The most prominent responses were up regulation of ABCA1 (0.11 + 0.04 p < 0.05) and 
NAMPT (0.16 + 0.07 p < 0.05) post SIT and glucose pre and post SIT. The up regulation of 
ABCA1 (p < 0.05) in response to glucose was significantly increased post SIT (Figure 3). 
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NMNAT1 was also up-regulated significantly in response to glucose both pre and post SIT 
(Figure 3). While SIRT5 and CD38 were down-regulated in response to glucose both pre and 
post SIT (Figure 3). In addition, HIC1 (p < 0.05), SIRT4 (p < 0.05), NMRK1 (p < 0.05), 
PSMB6 (p < 0.05), PARP1 (p < 0.05), SIRT2 (p < 0.05), SIRT3 (p < 0.05) and SIRT7 (p < 
0.01) showed significantly differing responses to OGTT pre and post SIT. Inter-individual 
variation in gene expression was observed in the genes that were shown to be significantly 
regulated in response to SIT.  
 
Vitamin B3 concentrations 
 
Decreased mean plasma vitamin B3 concentrations following SIT and in response to the 
OGTT were not significant (Figure 4A) with a wide range of responses observed pre to post 
SIT levels (range: -1.22µmol.L
-1
 to +0.59µmol.L
-1
). Thirteen of the 20 participants had 
reduced levels of vitamin B3 post SIT (Figure 4B).  
 
NAD: NADP ratio analysis 
 
Whole blood (n=11) NAD (p=0.91, mean decrease 1.6 ± 50nmol.L
-1
) and NADP (p=0.07, 
mean increase of 21.8 ± 36.3nmol.L
-1
) levels did not significantly change post SIT. The 
NAD: NADP ratio was significantly reduced after 4 weeks of SIT (p=0.014) compared with 
baseline measures (Figure 4C), with a mean decrease of 0.34 ± 0.47 (range: -0.37 to +0.04) 
(Figure 4D).  
 
NAMPT concentration 
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NAMPT concentrations did not change significantly post SIT at 0 (p=0.97), 60 (p=0.19) and 
120 (p=0.84) minute time points (Figure 4E). Inter-individual variation in NAMPT plasma 
concentrations were observed ranging from +0.051ng/mg and -0.043ng/mg (Figure 4F). 
 
Correlated SIRT/NAD gene expression and metabolic markers 
 
Expression of NAMPT, CD38, ABCA1 and NMNAT1 were all positively correlated following 
SIT, while pre SIT expression was not (Table 4). Correlations indicated post SIT NAMPT 
was positively associated with post SIT ABCA1 (r=0.696, p=0.001) and NMNAT1 (r=0.660, 
p=0.002). Additionally, post SIT ABCA1 was positively associated with post SIT CD38 
(r=0.615, p=0.004) and NMNAT1 (r=0.689, p=0.001). Post SIT measures of NMNAT1 
demonstrated positive relationships with post SIT measures of CD38 (r=0.459, p=0.042) and 
ABCA1 (r=0.689, p=0.001).  
 
Potential co-regulated expression of NAMPT, CD38, ABCA1 and NMNAT1 was further 
investigated by determining correlations with metabolic markers pre and post SIT. Notably, 
plasma glucose and cholesterols were associated with NAMPT and ABCA1 regulation. 
NAMPT and ABCA1 were positively correlated with post SIT, but not pre SIT fasted glucose 
(NAMPT r = 0.636, p = 0.003; ABCA1, r = 0.466, p = 0.038) (Table 5).  NAMPT and glucose 
AUC (r = 0.462, p = 0.04) were also positively correlated post SIT, but not pre SIT (Table 5). 
NAMPT was negatively correlated with LDL (r = -0.497, p = 0.03) (Table 5). NAMPT 
expression was also negatively associated with NAD: NADP ratio (r=-0.676, p=0.022) post 
SIT, but not pre SIT (Table 5).  
 
Principal Component and Partial Least Squares analysis  
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Principal Component Analysis (PCA) was applied to determine whether there were patterns 
discernible in the dataset that could be linked to the variable anthropometric and metabolic 
responses to SIT. PCA conducted on the entire hSIRTNAD gene expression dataset did not 
reveal obvious patterns. However, focus on the post SIT gene expression profiles resulted in a 
PCA biplot explaining 44% of the dataset variation (Figure 5A), with clustering of females 
participants, indicating differing responses of the sirtuin/NAD system to SIT compared to 
males and in their sirtuin/NAD system responses to SIT (Figure 5A). Partial Least Squares 
(PLS) analysis indicated associated body composition and metabolic factors distinguishing 
male and female responses to SIT using normalized hSIRTNADplex gene expression (Y) and 
anthropometric and metabolic marker data (X) (Figure 5B).  The PLS plot identified body fat 
levels as a factor associated with clustering of female participants (Figure 5B). Glucose and 
insulin are positioned further from female participants indicating that these factors may also 
differ in male and female participants in response to SIT (Figure 5B).  Notably, NAMPT and 
ABCA1 expression levels are closely associated with glucose and insulin levels (Figure 5B) 
reflecting the identified positive correlation post SIT (Table 5) providing further indication 
that these genes are responsive to glucose and insulin (Figure 4). 
 
Discussion  
 
Supervised SIT has emerged as a strategy to improve exercise performance and health, but as 
with all exercise there is clear inter-individual variation in responses (Ruchat et al. 2010). In 
support of previous reports this study observed improvements in body composition (Figure 
1), insulin sensitivity and lipid profiles in response to SIT. Interactions with individual 
genetics may be a factor in individual responses to exercise (Ruchat et al. 2010) and 
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transcriptional responses of the SIRT/NAD system to SIT were investigated to determine 
associations with the responses to SIT in blood samples.  
 
The sirtuin/NAD system consists of 7 sirtuin genes (SIRT1-7) and genes encoding enzymes 
that are involved in de novo synthesis of NAD from dietary tryptophan and vitamin B3. 
Additionally, there are a number of enzymes that are involved in recycling NAD to increase 
and up regulate sirtuin activity in order to maintain homeostasis and respond to various 
stressors (Ying 2008). This study measured blood profiles of the sirtuin/NAD system pre and 
post SIT to determine whether SIT led to a shift in the homeostatic sirtuin/NAD profile in 
each participant as opposed to focusing on acute effects of SIT. Corresponding shifts in other 
blood factors were considered in parallel two days post the final SIT session. Results of 
transcriptional profiling of blood from our volunteers indicated interactions with the sirtuin 
system, with small, but significant down regulation of CD38 (which depletes NAD) and up 
regulation of NMNAT1 and NAMPT (rate limiting enzymes in NAD synthesis) and ABCA1 (a 
lipid transporter that alters blood cholesterol). This evidence was further supported by 
correlations showing co-regulated expression of this small gene set (Table 4). Importantly, it 
is now well recognised that small changes in a gene set within a biochemical pathway are 
often related to biologically meaningful changes (Subramanian et al. 2005). The correlated 
gene expression of NAMPT, NMNAT1, CD38 and ABCA1 post SIT (Table 4) indicates that 
these may be key components of the sirtuin/NAD system responses to exercise training. 
Indeed, up-regulation of NAMPT and NMNAT1 may be a key response to increased demand 
for NAD in response to glucose and increased exercise. NAMPT activity elevates synthesis 
of nicotinamide mononucleotide (NMN), the rate limiting step for NMNAT1 conversion of 
NMN to NAD (for review see, Garten et al. 2015). However, reduced levels of plasma 
vitamin B3 post SIT (seen in 13 of the 20 participants) (Figure 4B) may reflect on the 
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increased demand for these rate-limiting enzymes to recycle NAD precursors. The 
corresponding down regulation of CD38 in response to glucose may be a compensatory 
factor to alleviate increased demand for NAD in regulating the response to elevated plasma 
glucose. NAMPT was negatively correlated with NAD:NADP ratios. This reduction in 
NAD:NADP ratios post SIT may be a factor prompting the up regulation of NAMPT and also 
the observed up regulation of NMNAT1. Reduced NAD:NADP ratios also imply depletion 
and or increased demand for NAD. This suggests that gaining further positive effects of 
exercise may be augmented by ensuring dietary sources of tryptophan and vitamin B3 are 
optimal for the individual. NAMPT has also emerged as player in glucose regulation 
(Hajianfar et al. 2012; Revollo et al. 2007). Further analysis was conducted to determine 
whether elevated NAMPT gene expression was associated with increased plasma NAMPT 
since it has been reported that elevated levels of intracellular NAMPT may lead to increased 
secretion of extracellular NAMPT (Yoon et al. 2015). Variations in extracellular NAMPT 
plasma levels were observed in the study participants and were not directly correlated with 
expression of NAMPT in blood. This may be attributed to differences in body fat levels in the 
study participants as studies have indicated that extracellular NAMPT may be primarily 
secreted from adipose tissue rather than blood cells (Berndt et al 2005; Yoon et al. 2015).   
 
PCA and PLS plots (Figure 5) indicated that the variation in sirtuin/NAD system responses to 
SIT may be attributed, in part, to sex differences. This is supported by a recent study 
reporting sex differences in response to 12 weeks of sprint interval training (Bagley et al. 
2016). Additionally, it was noted that individual male participants (IDs 1, 6 and 19) appeared 
to respond differently to SIT in comparison with the remainder of the male cohort (Figure 5). 
Furthermore, these three male participants had distinctly different responses from each other 
with respect to favourable improvements in body composition and metabolic markers post 
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SIT. Different responses were associated with body composition, glucose regulation and 
cholesterol levels and sirtuin system gene expression profiles. Previous studies have 
identified differing transcriptional profiles in muscle associated with individuals who 
demonstrate biological variation in responses to exercise (Keller et al. 2011). Incorporation of 
measurement of corresponding blood and tissue level sirtuin/NAD system transcriptional 
profiles in the design of future studies are desirable. Correlated profiles may provide further 
insights on individual responses to physical activity in tissues that are specifically targeted by 
training.  
  
The current pilot study was not without limitations. Due to technical issues we were not able 
to record power output during SIT and inter-individual variations in work could contribute to 
some of the differences observed. However, participants were asked to give a maximal effort, 
as the majority of SIT interventions do and rely on. The volunteers were supervised during 
each session and so any major issues with effort are unlikely. The current study did not 
account for hormonal differences at different points in the menstrual cycle and future work 
should consider hormone levels. However, irrespective of potential variation in menstrual 
status, sirtuin/NAD blood gene expression profiles show less variation when compared to 
males. It seems unlikely that menstrual status has a large effect. This study did not use a 
control group. Hence, a comparison with a group not participating in regular SIT sessions 
was not possible. Responses to SIT were thus compared within individuals using pre-SIT 
intervention measurements for comparison with post-SIT measurements. Extending SIT 
studies may facilitate assessments over a period when the study subjects refrain from SIT. It 
is difficult to provide an appropriate comparable control group for SIT. Monitoring of 
physical activity levels in the group not participating in SIT would be an important factor to 
reduce confounding responses during the intervention period. Habitual physical activity 
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levels were not assessed or whether these changed during the SIT period. All aspects of 
physical activity (not only the SIT) may alter the sirtuin/NAD system and should be 
considered in design of future studies.  
 
In conclusion, significant improvements in body composition parameters (body mass and 
body fat) were achieved in response to SIT, but associated significant improvements in mean 
levels of metabolic health parameters were not observed (Supplementary File S3). However, 
it was noted that although mean levels of metabolic health parameters did not reveal 
significant changes in response to SIT a number of participants did show improved glucose 
regulation and lipid profiles and associated transcriptional responses in the sirtuin/NAD 
system. Notably, metabolic improvements in response to SIT were achieved in individuals 
with poor health parameters measured pre-SIT. Furthermore, differences in female and male 
participants indicated that sex-specific factors may influence responses to SIT. This pilot 
study establishes criteria for designing future studies to investigate responses to SIT. In 
addition to male and female cohorts to determine sex specific effects, measurement of blood 
and tissue level profiles, the inclusion of a control group not undertaking increased physical 
activity, gathering additional data on lifestyle factors, such as habitual physical activity, will 
further inform interpretation of data analysis. Further investigation of the causes of the 
marked inter-individual variation in observed responses to SIT will be critical in formulating 
optimal public health messages for SIT and potentially other forms of exercise. 
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Table 1 NetWISP dietary analysis of macronutrient and niacin intake of participants prior to 
SIT 
 
Macro/micronutrient Mean ± SEM Recommended 
Intake 
Fat (% Total Daily Energy Intake) 33.6 ± 2.3 ≤35 
Protein (% Total Daily Energy Intake) 17.8 ± 0.9 ≤15 
Carbohydrate (% Total Daily Energy Intake) 44.5 ± 2.5 ≥50 
Alcohol (% Total Daily Energy Intake) 4.2 ± 1.5 <5 
Niacin (mg/day) 27.8 ± 3.1 13-17 
 
Note: data are presented as mean ± standard error of the mean (n=14). Macronutrient intakes are  
presented as a percentage of total daily energy intake; Niacin intake is presented in milligrams per day.  
Current recommended daily intakes of macronutrients and niacin are indicated. 
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Table 2 Anthropometric changes pre and post SIT 
 
Variable Pre SIT Post SIT 
Body Mass (kg) 73.6 ± 3.2 72.9 ± 3.1* 
BMI (kg/m
2
) 23.2 ± 0.6 23.1 ± 0.5 
Waist: hip ratio 0.81 ± 0.02 0.79 ± 0.01 
Body Fat (%) 21.6 ± 1.4 20.2 ± 1.3** 
Note: data are presented as mean ± standard error of the  
mean (n=20). Paired t-tests were used at a significance  
level of p<0.05. * indicates p<0.05; ** indicates p<0.01 
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Table 3 Plasma lipids, glucose and insulin 
Variable Pre SIT Post SIT 
Total Cholesterol (mmol l
-1
) 3.95 ± 0.157 3.87 ± 0.137 
HDL (mmol l
-1
) 1.36 ± 0.052 1.37 ± 0.068 
LDL (mmol l
-1
) 2.19 ± 0.150 2.08 ± 0.134 
Non-HDL (mmol l
-1
) 2.59 ± 0.179 2.50 ± 0.144 
HDL/LDL Ratio 1.69 ± 0.160 1.63± 0.141 
TRG (mmol l
-1
) 0.88 ± 0.102 0.93 ± 0.102 
Fasting Glucose (mmol l
-1
) 4.92 ± 0.114 4.87 ± 0.120 
Fasting Insulin (mU l
-1
) 5.95 ± 1.16 5.53 ± 0.50 
AUC Glucose (mmol l
-1
 2h
-1
) 624 ± 19.03 608 ± 19.42 
AUC Insulin (mU l
-1
 2h
-1
) 2717 ± 445.94 2523 ± 360.85 
                      Note: Mean levels were not significant (p<0.05) 
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Table 4 Correlation of sirtuin/NAD system genes and pre and post SIT 
 
Gene Time 
Point 
NAMPT CD38 ABCA1 
Pre SIT Post SIT Pre SIT Post SIT Pre SIT Post SIT 
ABCA1 Pre SIT 0.353 0.55* 0.434 -0.135   
Post SIT -0.15 0.696** -0.096 0.615**     
NMNAT1 Pre SIT -0.25 0.34 0.208 0.263 0.212 0.18 
Post SIT -0.35 0.66** 0.173 0.459* 0.245 0.689** 
Note: data are presented as R values. Pearson correlations were used at a significance level of p<0.05. * 
indicates p<0.05; ** indicates p<0.01. 
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Table 5 Correlations between gene expression and metabolic  
markers pre and post SIT  
 
Variable NAMPT ABCA1 
Pre SIT Post SIT Pre SIT Post SIT 
Fasted Glucose 0.426 0.636** 0.360 0.466* 
Glucose AUC 0.191 0.462* 0.360 0.378 
LDL -0.115 -0.497* 0.004 -0.449 
NAD: NADP 0.14 -0.68* 0.11 -0.004 
Note: data are presented as R values. Pearson correlations were used  
at a significance level of p<0.05. * indicates p<0.05; ** indicates  
p<0.01. AUC denotes area under the curve.  
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Figures 
 
 
Figure 1 Changes in individual anthropometric measures in response to SIT [A] body mass, 
[B] % body fat [C] BMI [D] waist: hip ratio (n=20). 
 
Figure 2 Plasma glucose, insulin and insulin sensitivity responses to SIT. [A] Mean ± SEM 
glucose area under the curve (AUC) pre and post SIT. [B] Individual glucose AUC changes 
post SIT. [C] Mean ± SEM insulin AUC pre and post SIT. [D] Individual insulin AUC 
changes post SIT. [E] Mean ± SEM insulin sensitivity pre and post SIT. [F] Individual insulin 
sensitivity changes post SIT. Paired t-tests were used on mean levels (n=20) at a significance 
level of p<0.05.  
 
Figure 3 Transcriptional responses of the SIRT/NAD system to SIT. Mean expression for 
each gene (n=20 + SEM) is shown pre-SIT, pre-SIT post OGTT, post SIT and post SIT post 
OGTT. Gene expression was assessed by hSIRTNADplex assay and normalised to internal 
reference gene UBE2D2. Significant (p < 0.05) differences in gene expression comparing 
pre-SIT to post SIT (a), pre SIT OGGT responses (b), post SIT OGGT responses (c) and pre 
SIT OGGT to post SIT OGTT responses (d) are indicated. 
 
Figure 4 Plasma vitamin B3 and NAD:NADP ratios. [A] Mean ± SEM plasma vitamin B3 
pre and post SIT (0) and post OGTT (1 and 2 hours) (n=20). [B] Individual plasma vitamin 
B3 changes post SIT. [C] Mean ± SEM NAD:NADP ratio pre and post SIT (n=11). [D] 
Individual NAD: NADP ratio changes post SIT. [E] Mean ± SEM plasma NAMPT pre and 
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post SIT (0) and post OGTT (1 and 2 hours) (n=20). [F] Individual plasma NAMPT changes 
post SIT. Paired t-tests were used at a significance level of p<0.05. 
 
Figure 5 Principal component (PCA) and partial least squares (PLS) analyses of UBE2D2 
normalised post SIT hSIRTNADplex gene expression and anthropometric and metabolic 
markers. Female (∆) and male (▲) participants are indicated. [A] PCA biplot post SIT. The 
PCA biplot permits visualisation of inherent clustering patterns of individuals and associated 
gene expression levels (denoted by ● and gene symbol). The measurements all fall within the 
Hotelling T2 95% confidence limit. [B] PLS analysis coefficients of weights of gene 
expression data (Y) and anthropometric and metabolic markers (X) post SIT. The 
anthropometric and metabolic markers are indicated in grey font. The PLS permits 
visualisation of associations between individuals and anthropometric and metabolic markers. 
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